GEMMABio Doses First Patient in CHARISMA Trial of GB221 Gene Therapy for SMA1

Next-generation gene therapy delivered directly to cerebrospinal fluid aims to treat severe childhood disease

Feb. 27, 2026 at 1:21am

Got story updates? Submit your updates here. ›

GEMMABio, a clinical-stage genetic medicines company, announced that the first patient has been dosed in the Phase 1/2 CHARISMA clinical trial of GB221, an investigational next-generation gene therapy for spinal muscular atrophy type 1 (SMA1). The CHARISMA trial is evaluating the safety, tolerability, and efficacy of GB221, which is delivered directly to the cerebrospinal fluid and designed to reduce overexpression-related toxicities and sensory neurotoxicity.

Why it matters

SMA1 is a severe, early-onset form of spinal muscular atrophy that typically leads to death by 18 months of age if untreated. GB221 represents a potential breakthrough treatment that could transform the lives of children and families affected by this devastating disease.

The details

The CHARISMA trial is the first clinical evaluation of a next-generation gene therapy for SMA1 delivered directly to the cerebrospinal fluid. GB221 was developed using proprietary central nervous system platform technology licensed from the University of Pennsylvania to express a functional, codon-optimized SMN1 gene and reduce overexpression-related toxicities. The trial will evaluate GB221 in pediatric participants from two weeks to younger than twelve months of age, including both symptomatic and presymptomatic patients.

  • The first patient was dosed in the CHARISMA trial on February 26, 2026.

The players

GEMMABio

A clinical-stage global genetic medicines company developing GB221 as an investigational next-generation gene therapy for SMA1.

James M. Wilson, MD, PhD

CEO of GEMMABio and a Member of the International Expert Advisory Board at Brazil's Casa dos Raros.

Jonas Morales Saute, MD, PhD

A neurologist and neurogeneticist at the Hospital de Clínicas de Porto Alegre in Brazil who is a principal investigator on the CHARISMA clinical trial.

Mario Moreira, PhD, MPH

President of Fiocruz, the Oswaldo Cruz Foundation, which has a partnership agreement with GEMMABio.

Got photos? Submit your photos here. ›

What they’re saying

“I would like to express our gratitude for the young child and family who were courageous in being the first to accept our investigational gene therapy for SMA1.”

— James M. Wilson, MD, PhD, CEO, GEMMABio (PRNewswire)

“The medical team is monitoring the first patient carefully, hoping to see therapeutic benefit and progress towards developmental milestones.”

— Jonas Morales Saute, MD, PhD, Principal Investigator, CHARISMA Trial (PRNewswire)

“The ongoing clinical study opens a front of action that can transform the lives of families and children who deal with the disease on a daily basis.”

— Mario Moreira, PhD, MPH, President, Fiocruz (PRNewswire)

What’s next

If GB221 meets criteria for a rare pediatric disease product application and is approved by the U.S. FDA, GEMMABio will be eligible to receive a priority review voucher that can be used to obtain a quicker FDA review of a future drug or sold to another company.

The takeaway

The CHARISMA trial represents a significant milestone in the development of a potential breakthrough treatment for the devastating SMA1 disease. The innovative gene therapy approach delivered directly to the cerebrospinal fluid aims to transform the lives of children and families affected by this rare and severe condition.